Latest Commercial Execution News

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

Enlitic delivered its strongest quarter yet with A$5.1 million in contracts, including significant agreements with Penn Medicine, St. Jude Children’s Research Hospital, and Parkland Health, while improving cash flow and advancing its AI-powered Ensight platform.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

RLF AgTech has posted its strongest trading period with $18.3 million revenue year-to-date and positive EBITDA in March, driven by a strategic reset under new CEO Stuart Upton and a $4.5 million capital raise.

EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.

HITIQ Limited's March quarter saw a remarkable 223% jump in sales to $294k, driven by the nationwide rollout of its PROTEQT™ concussion management system and initial international sales. The company bolstered its governance and advisory ranks while managing funding to support its commercial push.

Aurora Labs has made significant strides in commercial propulsion delivery and deepened its partnership with European defence giant MBDA, while scaling manufacturing capabilities and reinforcing its Board with defence expertise.

Energy Action Limited posted a milestone quarter ending March 2026, delivering positive operating cash flow for the first time in FY26 alongside strong revenue gains and a notable $0.5 million debt repayment. Governance changes add a layer of uncertainty ahead of a scheduled general meeting.